Diabetic Gastroparesis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Diabetic Gastroparesis pipeline market research report provides comprehensive information on the therapeutics under development for diabetic gastroparesis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Gastroparesis and features dormant and discontinued projects.
Key Targets in the Diabetic Gastroparesis Pipeline Market
The key targets in the diabetic gastroparesis pipeline market are 5-Hydroxytryptamine Receptor 4, D2 Dopamine Receptor, D3 Dopamine Receptor, 5-Hydroxytryptamine Receptor 3, Cannabinoid Receptor 1, and Tetrahydrobiopterin. 5-Hydroxytryptamine Receptor 4 has the highest number of pipeline products.
Diabetic Gastroparesis Pipeline Market, by Targets
For more target insights, download a free report sample
Key MoA in the Diabetic Gastroparesis Pipeline Market
The key MoA in the diabetic gastroparesis pipeline market are 5-Hydroxytryptamine Receptor 4 Agonist, D2 Dopamine Receptor Antagonist, D3 Dopamine Receptor Antagonist, 5-Hydroxytryptamine Receptor 3 Antagonist, Cannabinoid Receptor 1 Antagonist, and Tetrahydrobiopterin Replacement. 5-Hydroxytryptamine Receptor 4 Agonist has the highest number of pipeline products.
Diabetic Gastroparesis Pipeline Market, by MoA
For more MoA insights, download a free report sample
Key RoA in the Diabetic Gastroparesis Pipeline Market
The key RoA in the diabetic gastroparesis pipeline market are oral, intravenous, and subcutaneous. Oral has the highest number of pipeline products in the diabetic gastroparesis pipeline market. Oral has the highest number of pipeline products.
Diabetic Gastroparesis Pipeline Market, by RoA
For more RoA insights, download a free report sample
Key Molecule Type in the Diabetic Gastroparesis Pipeline Market
The key molecule type in the diabetic gastroparesis pipeline market are small molecule, gene therapy, monoclonal antibody. Small molecule has the highest number of pipeline products.
Diabetic Gastroparesis Pipeline Market, by Molecule Type
For more molecule type insights, download a free report sample
Key Companies in the Diabetic Gastroparesis Pipeline Market
The key companies in the diabetic gastroparesis pipeline market are Atlantic Healthcare Plc, Bird Rock Bio Inc, Johnson & Johnson, Neurogastrx Inc, PTC Therapeutics Inc, Suzhou Regend Therapeutics Co Ltd, Takeda Pharmaceutical Co Ltd, and Yuhan Corp.
Market report overview
Key targets | 5-Hydroxytryptamine Receptor 4, D2 Dopamine Receptor, D3 Dopamine Receptor, 5-Hydroxytryptamine Receptor 3, Cannabinoid Receptor 1, and Tetrahydrobiopterin |
Key MoA | 5-Hydroxytryptamine Receptor 4 Agonist, D2 Dopamine Receptor Antagonist, D3 Dopamine Receptor Antagonist, 5-Hydroxytryptamine Receptor 3 Antagonist, Cannabinoid Receptor 1 Antagonist, and Tetrahydrobiopterin Replacement |
Key RoA | Oral, Intravenous, and Subcutaneous |
Key molecule type | Small Molecule, Gene Therapy, Monoclonal Antibody |
Key companies | Atlantic Healthcare Plc, Bird Rock Bio Inc, Johnson & Johnson, Neurogastrx Inc, PTC Therapeutics Inc, Suzhou Regend Therapeutics Co Ltd, Takeda Pharmaceutical Co Ltd, and Yuhan Corp |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Gastroparesis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Diabetic Gastroparesis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Diabetic Gastroparesis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Diabetic Gastroparesis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Gastroparesis (Gastrointestinal)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Diabetic Gastroparesis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Diabetic Gastroparesis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Bird Rock Bio Inc
Johnson & Johnson
Neurogastrx Inc
PTC Therapeutics Inc
Suzhou Regend Therapeutics Co Ltd
Takeda Pharmaceutical Co Ltd
Yuhan Corp
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the diabetic gastroparesis pipeline market?
The key targets in the diabetic gastroparesis pipeline market are 5-Hydroxytryptamine Receptor 4, D2 Dopamine Receptor, D3 Dopamine Receptor, 5-Hydroxytryptamine Receptor 3, Cannabinoid Receptor 1, and Tetrahydrobiopterin.
-
What are the key MoA in the diabetic gastroparesis pipeline market?
The key MoA in the diabetic gastroparesis pipeline market are 5-Hydroxytryptamine Receptor 4 Agonist, D2 Dopamine Receptor Antagonist, D3 Dopamine Receptor Antagonist, 5-Hydroxytryptamine Receptor 3 Antagonist, Cannabinoid Receptor 1 Antagonist, and Tetrahydrobiopterin Replacement.
-
What are the key RoA in the diabetic gastroparesis pipeline market?
The key RoA in the diabetic gastroparesis pipeline market are oral, intravenous, and subcutaneous.
-
What are the key molecule type in the diabetic gastroparesis pipeline market?
The key molecule type in the diabetic gastroparesis pipeline market are small molecule, gene therapy, monoclonal antibody.
-
What are the key companies in the diabetic gastroparesis pipeline market?
The key companies in the diabetic gastroparesis pipeline market are Atlantic Healthcare Plc, Bird Rock Bio Inc, Johnson & Johnson, Neurogastrx Inc, PTC Therapeutics Inc, Suzhou Regend Therapeutics Co Ltd, Takeda Pharmaceutical Co Ltd, and Yuhan Corp.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.